{{Expand language|1=en|time=2021-01-26T13:45:04+00:00}}
{{medical}}
{{Drugbox
| Verifiedfields = verified
| Watchedfields = verified
| verifiedrevid = 488624854
| IUPAC_name = Estra-1,3,5(10)-triene-3,17β-diol, polymer with phosphoric acid
| image = Polyestradiol phosphate.svg
| width = 250px
| image2 = Estradiol phosphate molecule ball.png
| width2 = 225px
| caption2 = 上圖：聚磷酸雌二醇的[[键线式|键线式]]，下圖：{{le|雌二醇磷酸酯|estradiol phosphate}}（聚磷酸雌二醇的[[单体|单体]]）的[[球棒模型|球棒模型]]

<!-- Clinical data -->
| tradename = Estradurin, Estradurine
| Drugs.com = {{drugs.com|international|polyestradiol-phosphate}}
| pregnancy_category = 禁忌<ref name="Pharmanovia-Estradurin" />
| legal_status = Rx-only
| routes_of_administration = [[肌肉注射|肌肉注射]]<ref name="Pharmanovia-Estradurin" /><ref name="pmid10230677" />
| class = 雌激素藥物、{{le|雌激素酯|Estrogen ester}}

<!-- Pharmacokinetic data -->
| bioavailability = 肌肉注射: 高
| protein_bound = 雌二醇：~98%（和{{le|人血清白蛋白|human serum albumin|albumin}}及[[性激素結合球蛋白|SHBG]]）<ref name="pmid23375353">{{cite journal|last1=Stanczyk|first1=Frank Z.|last2=Archer|first2=David F.|last3=Bhavnani|first3=Bhagu R.|title=Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment|journal=Contraception|volume=87|issue=6|year=2013|pages=706–727|issn=0010-7824|doi=10.1016/j.contraception.2012.12.011|pmid=23375353}}</ref><ref name="FalconeHurd2007">{{cite book|author1=Tommaso Falcone|author2=William W. Hurd|title=Clinical Reproductive Medicine and Surgery|url=https://books.google.com/books?id=fOPtaEIKvcIC&pg=PA22|year=2007|publisher=Elsevier Health Sciences|isbn=978-0-323-03309-1|pages=22,362,388}}</ref><ref name="Pharmanovia-Estradurin" />
| metabolism = 主要是靠[[肝臟|肝臟]]，少部份會透過[[腎|腎]]、[[生殖腺|生殖腺]]及[[肌肉|肌肉]]（透過[[磷酸酶|磷酸酶]]）<ref name="Pharmanovia-Estradurin" />
| metabolites = 雌激素藥物、[[磷酸|磷酸]]及雌激素的[[代謝產物|代謝產物]]<ref name="OettelSchillinger2012">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|url=https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA261|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|page=261,544|quote=Natural estrogens considered here include: [...] Esters of 17β-estradiol, such as estradiol valerate, estradiol benzoate and estradiol cypionate. Esterification aims at either better absorption after oral administration or a sustained release from the depot after intramuscular administration. During absorption, the esters are cleaved by endogenous esterases and the pharmacologically active 17β-estradiol is released; therefore, the esters are considered as natural estrogens.}}</ref><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | s2cid = 24616324 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref>
| elimination_half-life = PEP: 70 days (10 weeks)<ref name="pmid8610057">{{cite journal | vauthors = Stege R, Gunnarsson PO, Johansson CJ, Olsson P, Pousette A, Carlström K | title = Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients | journal = Prostate | volume = 28 | issue = 5 | pages = 307–10 | date = May 1996 | pmid = 8610057 | doi = 10.1002/(SICI)1097-0045(199605)28:5<307::AID-PROS6>3.0.CO;2-8 }}</ref><br />Estradiol: 1–2 hours<ref name="pmid7169965">{{cite journal | vauthors = Düsterberg B, Nishino Y | title = Pharmacokinetic and pharmacological features of oestradiol valerate | journal = Maturitas | volume = 4 | issue = 4 | pages = 315–24 | year = 1982 | pmid = 7169965 | doi = 10.1016/0378-5122(82)90064-0}}</ref>
| excretion = [[尿|尿]]）（依[[生物轉化作用|生物轉化作用]]）<ref name="Pharmanovia-Estradurin" />

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 28014-46-2
| ATC_prefix = L02
| ATC_suffix = AA02
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB09369
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1201477
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = None
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P14877CDX2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07434
| PubChemSubstance = 51091766
| synonyms = PEP; Estradiol phosphate polymer; Estradiol 17β-phosphate polymer; Estradiol polymer with phosphoric acid; Leo-114

<!-- Chemical data -->
| chemical_formula = (C<sub>18</sub>H<sub>23</sub>O<sub>4</sub>P)<sub>n</sub><br />(n = variable; {{Overline|n}} = 13)
| molecular_weight = [[聚合物|聚合物]]: 不固定<br />{{le|重覆單元|Repeat unit}}: 334.347 g/mol

<!--Physical data-->
| melting_point = 195
| melting_high = 202
}}
'''聚磷酸雌二醇'''（Polyestradiol phosphate），簡稱PEP，藥品名稱Estradurin，是用來治療男性[[前列腺癌|前列腺癌]]的{{le|雌激素 (藥物)|Estrogen (medication)|雌激素}}藥品<ref name="Pharmanovia-Estradurin">{{Cite web |url=http://pharmanovia.com/product/estradurin/ |title=Archived copy |access-date=2018-01-01 |archive-url=https://web.archive.org/web/20180102072958/http://pharmanovia.com/product/estradurin/ |archive-date=2018-01-02 |url-status=dead }}</ref><ref name="pmid7483157">{{cite journal | vauthors = Stege R, Carlström K, Hedlund PO, Pousette A, von Schoultz B, Henriksson P | title = Intramuskuläres Depotöstrogen (Estradurin) in der Behandlung von Patienten mit Prostatakarzinom. Historische Aspekte, Wirkungsmechanismus, Resultate und aktueller klinischer Stand | trans-title = Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status | language = de | journal = Urologe A | volume = 34 | issue = 5 | pages = 398–403 | date = September 1995 | issn = 0340-2592 | pmid = 7483157 | quote = More than 50 years ago, orally given estrogen was already used in the treatment of prostate cancer. Due to cardiovascular side-effects with a high morbidity of 25%, this treatment has not become standard. Recent investigations show that parenteral application reduces the risk of cardiovascular side-effects, because it avoids the first passage through the liver with high concentrations of estrogen which normally occur after oral application. Therefore, an increased synthesis of so-called "steroid-sensitive" liver proteins, such as coagulation factors (especially factor VII) can be avoided. This newer parenteral estrogen application shows encouraging results of a cheap and effective hormonal therapy with a low rate of side-effects in patients with prostate cancer.}}</ref><ref name="pmid10230677">{{cite journal | vauthors = Mikkola A, Ruutu M, Aro J, Rannikko S, Salo J | title = The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium | journal = Ann Chir Gynaecol | volume = 88 | issue = 1 | pages = 18–21 | year = 1999 | issn = 0355-9521 | pmid = 10230677 | quote = Orchiectomy and estrogens have been used for over 50 years in the treatment of advanced prostatic cancer. Although orchiectomy is a simple procedure, it may cause psychological stress. Oral estrogen therapy is as effective as orchiectomy in terms of cancer inhibitory effect, but its acceptance as primary hormonal treatment is overshadowed by an increased risk of cardiovascular complications. Parenteral estrogen, polyestradiol phosphate (PEP), is effective, but also associated with cardiovascular complications, although to a lesser extent. During the last 20 years, well tolerated luteinizing hormone releasing hormone (LHRH) analogues have been replacing orchiectomy and estrogens. Efforts have been made to increase the efficacy of the treatment by adding antiandrogens to LHRH analogues and also to orchiectomy (combined androgen blockade, CAB). However, the efficacy of LHRH analogues and CAB has not proved to be superior to that of simple orchiectomy and, moreover, they are expensive treatment modalities. Orchiectomy and LHRH analogues are associated with negative effects on bone mass and may cause osteoporosis, whereas PEP treatment has an opposite effect. Parenteral polyestradiol phosphate is still a cheap potential treatment for advanced prostatic cancer, but further studies should be conducted to establish its future role, e.g. combining acetylsalicylic acid to prevent cardiovascular complications.}}</ref><ref name="pmid17219379">{{cite journal |last1=Mikkola|first1=A|last2=Aro|first2=J|last3=Rannikko|first3=S|last4=Ruutu|first4=M|title=Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy |journal=Prostate |volume=67 |issue=4 |pages=447–55 |date=March 2007 |pmid=17219379 |doi=10.1002/pros.20547 |last5=Finnprostate |first5=Group|s2cid=20549248}}</ref>。也可以用來作為治療女性的[[乳癌|乳癌]]、是治療{{le|低雌激素症|hypoestrogenism}}及[[更年期|更年期]]症狀的[[激素替代療法|激素替代療法]]藥物之一，也是給[[跨性別女性|跨性別女性]]的女性化[[跨性别激素疗法|賀爾蒙治療]]<ref name="Pharmanovia-Estradurin" /><ref name="Urdl2009">{{cite journal | last1 = Urdl | first1 = W. | title = Behandlungsgrundsätze bei Transsexualität | trans-title = Therapeutic principles in transsexualism | language = de | journal = Gynäkologische Endokrinologie | volume = 7 | issue = 3 | year = 2009 | pages = 153–160 | issn = 1610-2894 | doi = 10.1007/s10304-009-0314-9| s2cid = 8001811 }}</ref>，以每4個星期一次肌肉注射的方式給藥<ref name="Pharmanovia-Estradurin" /><ref name="pmid10230677" /><ref name="pmid25951459">{{cite journal | vauthors = Steinbach T, Wurm FR | title = Poly(phosphoester)s: A New Platform for Degradable Polymers | journal = Angew. Chem. Int. Ed. Engl. | volume = 54 | issue = 21 | pages = 6098–108 | year = 2015 | pmid = 25951459 | doi = 10.1002/anie.201500147 }}</ref>。

==参考文献==
{{reflist}}
{{Estradiol}}
[[Category:共聚物|Category:共聚物]]
[[Category:前药|Category:前药]]
[[Category:前列腺癌|Category:前列腺癌]]
[[Category:合成雌激素类|Category:合成雌激素类]]